Qnovia, Inc. Announces the Appointment of Four New Members to its Scientific Advisory Board
Published
RICHMOND, Va.--(BUSINESS WIRE)--Qnovia, Inc., a pharmaceutical company developing inhaled therapeutics across a variety of indication areas leveraging its proprietary inhaled drug delivery platform, the RespiRxTM, today announced the appointment of four new members to its Scientific Advisory Board (SAB). The new members include Neal Benowitz, MD, Professor at University of California at San Francisco, Ian M. Fearon, PhD, independent consultant, Darla E. Kendzor, PhD, Professor at University of
Full Article